Patents. Law. Pharma.
917.609.2296
BLOG
CRISPR-Cas9: After oral argument, Broad likely to prevail—but is it failure of the patent system?
On April 30, the Federal Circuit convened oral argument in the highly-watched patent case between UC and Broad over the interference proceeding covering patents for CRISPR-Cas9. (An overview of the case and the respective arguments were published in an earlier post.) The hotly-contested argument suggests the Court is leaning towards Broad, but raises deeper questions about whether this is a success or failure for the patent system.